Pharmacokinetics of pidotimod in elderly volunteers and in renal failure patients.
The pharmacokinetics of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) in elderly volunteers and in patients with renal failures were investigated. No differences in absorption, excretion and pharmacokinetic parameters was evident between old volunteers and the youngs of a previous work. Patients with impaired renal function showed different pharmacokinetic parameters of pidotimod in relation to different grade of kidney function. There were linear relationships between elimination half-lives and plasma levels of creatinine and urea; longer half-lives correspond to higher levels of creatinine and urea. As the half-life of the compound did never exceed 8-9 h, the data do not support any change of pidotimod administration schedule (every 24-12 h).
Spotti
D
D
S. Raphael Hospital, Dialysis Department, University of Milan, Italy.
Biffi
M
M
Coppi
G
G
Silingardi
S
S
Mailland
F
F
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006207:Half-Life; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D011761:Pyrrolidonecarboxylic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D051437:Renal Insufficiency / Q000378:metabolism*; D013844:Thiazoles / Q000009:adverse effects / Q000493:pharmacokinetics*; D053778:Thiazolidines; D014508:Urea / Q000097:blood
D007155:Immunologic Factors; D013844:Thiazoles; D053778:Thiazolidines; C064893:pidotimod; D014508:Urea; D011761:Pyrrolidonecarboxylic Acid